47 unknown, 42 completed, 5 not yet recruiting, 5 recruiting. 110 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 110 | Unknown 47, Completed 42, Not yet recruiting 5, Recruiting 5, Terminated 5, Active not recruiting 4, Withdrawn 2 |
Follow Chronic Hepatitis B: new trials by email Literature Review of Chronic Hepatitis B trials Research Report on Chronic Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 80 | 2026-01-11 | 2026-01-16 |
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 60 | 2026-01-11 | 2026-01-16 |
| Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach Tenofovir Alafenamide (TAF), Community-Based Support, Simplified WHO 2024 Criteria - Chronic Hepatitis B, Hepatitis B Virus Infection | Phase 4 | Not yet recruiting | The Task Force for Global Health | 6000 | 2026-01-01 | 2025-12-02 |
| Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients Peg-IFN α-2b combined with NAs - Metabolic Dysfunction-Associated Steatotic Liver Disease, Chronic Hepatitis B | Phase 4 | Not yet recruiting | Shenzhen Third People's Hospital | 830 | 2025-08-15 | 2025-07-17 |
| Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg PegIFN alfa-2b, PegIFN alfa-2b and NUC - Chronic Hepatitis B | Phase 4 | Not yet recruiting | Huashan Hospital | 360 | 2025-04-01 | 2025-03-28 |
| ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection Anti-PD-L1 antibody (ASC22), Nucleotide analogs, Peg-IFNα - Chronic Hepatitis b | Phase 4 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 120 | 2024-05-21 | 2026-09-01 |
| SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus Dapagliflozin 10mg Tab, Placebo 10mg Tab - Chronic Hepatitis B | Phase 4 | Recruiting | Chinese University of Hong Kong | 412 | 2024-03-26 | 2026-03-18 |
| Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT） Peg-Interferon α - Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b | Phase 4 | Recruiting | First Affiliated Hospital of Wenzhou Medical University | 1500 | 2024-01-01 | 2024-04-16 |
| Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients Empagliflozin 10 MG, Placebo pills - Chronic Hepatitis b, NAFLD | Phase 4 | Active not recruiting | The University of Hong Kong | 106 | 2022-01-02 | 2026-01-30 |
| The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China Tenofovir Alafenamide 25 MG, Sofosbuvir / Velpatasvir - Chronic Hepatitis C, Chronic Hepatitis B | Phase 4 | Unknown | Peking University First Hospital | 120 | 2021-08-01 | 2021-08-09 |
| Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection Tenofovir Alafenamide 25 MG - Safety Issues, Chronic Hepatitis B | Phase 4 | Active not recruiting | Taichung Veterans General Hospital | 52 | 2021-06-22 | 2026-05-04 |
| Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women Tenofovir Alafenamide Tablets - Chronic Hepatitis b, Tenofovir Alafenamide Fumarate | Phase 4 | Recruiting | First People's Hospital of Hangzhou | 50 | 2021-05-06 | 2025-09-08 |
| Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B Tenofovir Alafenamide fumarate 25mg Oral Tablet - Chronic Hepatitis B, Mother-to-Child Transmission | Phase 4 | Unknown | The First Affiliated Hospital of Zhengzhou University | 240 | 2021-04-26 | 2021-04-23 |
| Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) Tenofovir alafenamide - Chronic Hepatitis B | Phase 4 | Unknown | Jidong Jia | 100 | 2021-04-20 | 2023-05-23 |
| Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Vemlidy - Chronic Hepatitis b, Hepatitis B Reactivation | Phase 4 | Active not recruiting | National Taiwan University Hospital | 260 | 2020-09-09 | 2026-02-24 |
| The Effectiveness and Safety of Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase and Significant Liver Injury. Tenofovir Alafenamide - Chronic Hepatitis b | Phase 4 | Unknown | National Cheng-Kung University Hospital | 40 | 2020-05-14 | 2020-12-22 |
| Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines Tenofovir Alafenamide - Chronic Hepatitis b | Phase 4 | Active not recruiting | Young-Suk Lim | 780 | 2019-02-18 | 2024-12-17 |
| The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg Peginterferon Alfa, Nucleoside Analog (Substance) - Chronic Hepatitis B | Phase 4 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 200 | 2019-01-01 | 2019-01-15 |
| Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK) Stop current treatment (anti-HBV neucleos(t)ides), Keep current treatment (anti-HBV neucleos(t)ides) - Chronic Hepatitis B | Phase 4 | Recruiting | Humanity & Health Medical Group Limited | 2000 | 2018-12-01 | 2025-03-24 |
| Effect of Serum Vitamin D Level on the Efficacy of Peg-interferon Treatment in CHB Vitamin D - Chronic Hepatitis b | Phase 4 | Completed | Third Affiliated Hospital, Sun Yat-Sen University | 90 | 2018-12-01 | 2023-03-03 |
Showing 20 of 110. Sign in to see all of them.
Hepatitis B, Chronic (110) · Hepatitis B (15) · Liver Cirrhosis (5) · Hepatitis (3) · Bronchiolitis Obliterans Syndrome (2) · Fibrosis (2) · Non-alcoholic Fatty Liver Disease (2) · Carcinoma, Hepatocellular (1) · DNA Virus Infections (1) · Fatty Liver (1) · HIV Seropositivity (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Hepatitis D, Chronic (1) · Hepatitis, Chronic (1)
Blood-Borne Infections (110) · Chronic Disease (110) · Communicable Diseases (110) · Digestive System Diseases (110) · Disease Attributes (110) · Hepadnaviridae Infections (110) · Hepatitis, Viral, Human (110) · Infections (110) · Liver Diseases (110) · Pathologic Processes (110) · Pathological Conditions, Signs and Symptoms (110) · Virus Diseases (110) · DNA Virus Infections (109) · Hepatitis, Chronic (109) · Hepatitis (107)
entecavir (31) · Tenofovir (25) · Lamivudine (15) · adefovir dipivoxil (15) · peginterferon alfa-2a (15) · adefovir (13) · Telbivudine (11) · tenofovir alafenamide (11) · clevudine (7) · peginterferon alfa-2b (4) · nas (3) · Thymalfasin (2) · lipoarabinomannan (2) · 18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate (1) · Engerix-B (1)
Third Affiliated Hospital, Sun Yat-Sen University (7) · Bukwang Pharmaceutical (6) · Korea University (5) · Foundation for Liver Research (4) · GlaxoSmithKline (4) · National Taiwan University Hospital (4) · Novartis Pharmaceuticals (4) · Yonsei University (4) · Beijing Ditan Hospital (3) · Chinese University of Hong Kong (3) · Gilead Sciences (3) · Huashan Hospital (3) · Nanfang Hospital, Southern Medical University (3) · Beijing 302 Hospital (2) · E-DA Hospital (2)
China (42) · South Korea (28) · Taiwan (14) · Hong Kong (6) · Netherlands (5) · Singapore (4) · Canada (3) · Germany (3) · Turkey (Türkiye) (3) · United States (3) · Greece (2) · Italy (2) · Poland (2) · Romania (2) · Spain (2)
Pei-Jer Chen, M.D., Ph.D. (3) · Hyung Joon Yim, M.D. (2) · Qin Ning (2) · Qing-Lei Zeng, M.D. (2) · Sang Hoon Ahn, MD, PhD (2) · Zhiliang Gao, Doctor (2) · Belinda Jump (1) · Byoung Kuk Jang, M.D (1) · Calvin Pan, MD (1) · Chang Don Lee (1) · Chang Wook Kim, M.D (1)
PMID 28404091, PMID 28404092, PMID 19187608, PMID 20049753, PMID 21182232, PMID 22436845, PMID 23046671, PMID 23518903, PMID 24915612, PMID 25348661, PMID 30689258, PMID 35599306, PMID 10051494, PMID 12606735, PMID 14697813, PMID 15014185, PMID 15470215, PMID 15987917, PMID 16391218, PMID 16525137, PMID 16530509, PMID 16673294, PMID 17239478, PMID 17935165, PMID 18094378, PMID 19027013, PMID 19052126, PMID 19092267, PMID 19207973, PMID 19376603, PMID 19469708, PMID 19669255, PMID 19714720, PMID 19729084, PMID 20037275, PMID 21332542, PMID 21374657, PMID 22045673, PMID 22273662, PMID 22343511, PMID 23219442, PMID 23245604, PMID 23744454, PMID 24133668, PMID 24183313, PMID 24594870, PMID 24833635, PMID 24954675, PMID 25187919, PMID 25381721